Telmisartan vs Placebo: Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0171 | 0.0144 | 0.0203 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0207 | 0.0177 | 0.0243 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00362 | -0.00809 | 0.000809 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.825 | 0.653 | 1.04 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.822 | 0.647 | 1.04 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Telmisartan than on Placebo | 276 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Telmisartan | Consists of patients in the two treatment groups: ASA+ERDP + telmisartan and Clopidogrel + telmisartan | 125 | 7,306 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Consists of patients in the two treatment groups: ASA+ERDP + placebo and Clopidogrel + placebo | 151 | 7,283 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only) | ClinicalTrials.gov |
| Description | ClinicalTrials.gov | |
| Time frame | Randomization to final patient contact | ClinicalTrials.gov |
| Population | Patients who did not have diabetes mellitus at baseline were analyzed as randomized and were included in the analysis until final patient contact regardless of whether they were still on treatment. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | ClinicalTrials.gov |
| NCT number | NCT00153062 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Stroke | ClinicalTrials.gov |
| Interventions | Aggrenox, Aggrenox, Clopidogrel placebo, Clopidogrel placebo, Micardis, Micardis, Aggrenox placebo, Aggrenox placebo, Clopidogrel, Clopidogrel, Micardis placebo, Micardis placebo | ClinicalTrials.gov |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2009-09-02 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00153062?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.